Navigation Links
Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
Date:7/14/2014

RESEARCH TRIANGLE PARK, N.C., July 14, 2014 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today the expansion of its drug design and development program. The company has been granted supercomputing time at Argonne National Laboratory to design inhibitors of multiple parasitic targets. 

Through a discretionary allocation of 1 million core-hours at the Argonne Leadership Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will use Mira, a 10-petaflops IBM Blue Gene/Q supercomputer to investigate inhibitors of the dihydrofolate reductase enzyme, or DHFR, from multiple sources. The purpose is to identify leading drug candidates for broad-impact, anti-parasitic therapeutics targeting several orphan diseases including malaria. The results will be published to the scientific community and general public. Preclinical development is expected to follow.

"Very often, the same protein will mutate and cause different types of illness or disease. Targeting this protein at a molecular level helps to identify a more effective treatment protocol," says Ed Addison, CEO of Cloud Pharmaceuticals.

Cloud Pharmaceuticals is using a highly parallel, quantum mechanics/molecular mechanics (QM/MM) computational chemistry algorithm and bioinformatics tools to increase the accuracy of the algorithms used in drug discovery. Cloud Pharmaceuticals also uses its Inverse Design in silico drug design technology and applies novel artificial intelligence algorithms to search through large portions of molecular space to identify the best drug candidates.

About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. We accelerate the drug discovery and design process in a way that delivers tangible results and true value for our partners. For information visit www.cloudpharmaceuticals.com.


'/>"/>
SOURCE Cloud Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. ScaleMatrix Leads the Way Unveiling the Industry’s First Transparent Pricing Tool in Private Cloud Offerings
2. Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market - Global Trends, Challenges, Opportunities & Forecasts (2012 - 2017)
3. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
4. MUSA's Validated Cloud: Fully Qualified Citrix® Application Delivery - IQ & OQ Library Now Includes: NetScaler® & XenApp®
5. Salk scientists use Amazon Cloud to view molecular machinery in remarkable detail
6. Adeptia Named a Value Leader in EMA Radar for Integration Technologies for Hybrid Cloud: Q4 2012
7. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
8. Chemical Publishing Company Partners with Author Cloudware for a Digital eBook Distribution for Water Treatment, Waste Water Treatment, and Cooling Water Treatment Titles
9. Nimbix and Convey Partner for “The Accelerated Genomics Cloud” (TAGC) Promotion
10. Spaulding Clinical to Showcase First Cloud-based Cardiac Safety Solution Fully Integrated with Medidata Clinical Cloud at DIA
11. Controlling magnetic clouds in graphene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid ... defining the optimal patient population and timing of blood sampling may improve the ...
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer — a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast details ... Company,s Annual and Special Meeting. The Zenith ... Thursday, December 15, 2016 at Mount Royal ... Mount Royal Gate SW, Calgary, Alberta , ... management information circular, containing the matters to be considered at ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):